TARA-002 Shows Durable Complete Response in BCG-Unresponsive Bladder Cancer—68% Response at Six Months and Favorable Safety Profile Revealed
Market Chameleon (Tue, 24-Feb 7:55 AM)
Protara Therapeutics Begins Phase 3 THRIVE-3 Trial Targeting Choline Deficiency in Long-Term Parenteral Support Patients
Market Chameleon (Wed, 7-Jan 9:02 AM)
TARA-002 Wins Dual FDA Breakthrough and Fast Track Status—What Does This Mean for Pediatric Lymphatic Malformations?
Market Chameleon (Mon, 5-Jan 8:39 AM)
